RxDoctor Payments Data

John Roussalis

Plastic and Reconstructive Surgery · Newark, DENPI 1235252669

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.5%), food and beverage and gifts — rather than concentrated in one kind of arrangement. Kerecis Limited accounts for 62.1% of it on its own, with 26 other manufacturers making up the rest.

$13,242in general payments, 2019–2025

Across 115 payments — averaging $115.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$8K
  • AbbVie$3K
  • BD$350
  • Johnson & Johnson$257
  • Convatec Inc.$207
  • UCB, Inc.$162
  • plus $1K from 21 others

What the payments were for

  • Speaking & faculty fees$7,35056%
  • Food & beverage$3,01123%
  • Gifts$2,88122%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few plastic and reconstructive surgery providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$3,505,777
Medicare patients
730
Services billed
5,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.35$18,463
Mupirocin147$1,028
Doxycycline Hyclate99$714
Cephalexin89$421
Clindamycin Hcl40$216
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$155$18,46335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few plastic and reconstructive surgery providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other plastic and reconstructive surgery in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →